The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017

BACKGROUND: Most Canadian provinces and territories rely on the pan-Canadian Oncology Drug Review (pCODR) to provide recommendations regarding public reimbursement of cancer drugs. The pCODR review process considers four dimensions of value—clinical benefit, economic evaluation, patient-based values...

Descripción completa

Detalles Bibliográficos
Autores principales: Skedgel, Chris, Wranik, Dominika, Hu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840198/
https://www.ncbi.nlm.nih.gov/pubmed/29353385
http://dx.doi.org/10.1007/s40273-018-0610-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840198/
https://www.ncbi.nlm.nih.gov/pubmed/29353385
http://dx.doi.org/10.1007/s40273-018-0610-0

Ejemplares similares